anselamimab

News

AstraZeneca's light chain (AL) amyloidosis candidate anselamimab has failed a phase 3 readout, but showed efficacy in a patient subgroup.

News

A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.